NASDAQ · EDIT
Editas Medicine, Inc.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
Loading market information…
NASDAQ · CABA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cabaletta Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cabaletta Bio, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.33. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cabaletta Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 15, 2025 |
| -$0.71-5.97% vs estimate |
| $0.00 |
| Q4 2024 | Mar 31, 2025 | -$0.650.0% vs estimate | $1.64M |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.62-5.08% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$1.25-$0.05 (-3.85%)
Allogene Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.97% below the high.
$6.63+$0.40 (+6.42%)
Capricor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.58% below the high.
$5.85-$0.04 (-0.68%)
Kyverna Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$11.31+$0.38 (+3.43%)
Lyell Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.88% below the high.
$3.06-$0.07 (-2.24%)
Lexeo Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 72.16% below the high.
$1.44+$0.03 (+2.13%)
ProQR Therapeutics N.V.’s quoted price sits in the lower half of its reported 52-week range, 48.75% below the high.
